How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials

Expert Opin Emerg Drugs. 2023 Dec;28(4):213-216. doi: 10.1080/14728214.2023.2264182. Epub 2023 Dec 26.

Authors

Andrea Esposito¹, Paolo Bossi^{2

3}

Affiliations

¹ Department of Medical and Surgical Specialities, Radiological Sciences and Public Health, ASST-Spedali Civili Brescia, University of Brescia, Oncology Unit, Piazzale Spedali Civili, Brescia, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
³ IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

PMID: 37750491
DOI: 10.1080/14728214.2023.2264182

No abstract available

Keywords: Diarrhea; chemotherapy; immune-check point inhibitors; oncology; target therapy.

Publication types

Editorial

MeSH terms

Clinical Trials, Phase II as Topic
Diarrhea* / prevention & control
Humans
Neoplasms* / complications